

# MBIM735: Advanced Immunology Treg therapy

#### Leonardo M.R. Ferreira

Microbiology and Immunology, Regenerative Medicine and Cell Biology
Hollings Cancer Center
Medical University of South Carolina

#### Immune tolerance







Versatile

Multi-faceted

Many suppressive mechanisms

A therapy?







Versatile


Multi-faceted

Many suppressive mechanisms

A therapy?








Ferreira et al, Nat Rev Drug Discov 2019


## Clinical trials with Tregs




### Treg therapy for type 1 diabetes


**In mice:** 2 x 10<sup>6</sup> BDC2.5 Ag-specific Tregs together with syngeneic islet transplant revert autoimmune diabetes

**In humans:** 2 x 10<sup>9</sup> polyclonal Tregs are safe for type 1 diabetes patients but do not ameliorate disease






### Treg therapy for organ transplant




Regulatory cell therapy allows for lower doses of immunosuppressive drugs and leads to less infections

#### How can we put Treg therapy in the fast lane?




#### Chimeric antigen receptor (CAR)










TCR/CD3 complex


Co-stimulatory receptors




**CAR** 




#### Type 1 diabetes




#### Treating type 1 diabetes using CAR Tregs




#### Treating type 1 diabetes using CAR Tregs




#### Islet transplant as a treatment for T1D



## Anti-HLA-A2 CAR Tregs for HLA-A2+ islets transplants to treat T1D




#### Grafting A2-CAR scFv specificity




#### A2-CAR Tregs recognize HLA-A2









#### Treg activation



#### Immunogenic eplets in HLA-A2



## A2-CAR Tregs recognize the 144TKH eplet, not 44RME, 105S or 127K



44RME: A11, A24, A31

105S: A24, A31

127K: A24


A2-CAR Tregs co-incubated with allogeneic human islets

### How to best genetically modify human Tregs?

a FDA approved (costly and time-consuming to produce)


Retroviruses or lentiviruses Pseudodiploid single-stranded RNA Cytoplasm Reverse transcription Nucleus Double-stranded DNA Random integration Multiple copies integrated

#### Adeno-associated viruses




**b** Not yet FDA approved (faster and cheaper to produce)


#### Non-viral approaches



## Reprogramming Treg specificity





#### A2-CAR Tregs suppress Teff cell proliferation





#### A2-CAR Tregs prevent graft-vs-host disease






#### A2-CAR Tregs traffic to A2+ human islet grafts

Kidney capsule exposure




Human A2+ islet transplant




Luciferase+ A2-CAR Treg i.v. injection





#### Outstanding questions and future directions

- Does CAR Treg survival and/or function suffer with TCR ablation?
- What unique challenges do CAR Tregs face in pancreatic islets? Inflammation? Insulin? IL-2 deprivation?
- Can CAR Tregs prevent T1D in humans? Reverse it?
- What are the best targets and CAR designs for T1D CAR Tregs?
- What is the best source for T1D CAR Tregs?



Ferreira et al, Nat Rev Drug Discov 2019

## Designer immunology



